Micro- and Nanoplastics: Will the US Recognize This as a Potential Health Threat?
Donald J. Trump has been elected the next President of the United States, and the Senate and the House of ...
Read moreDonald J. Trump has been elected the next President of the United States, and the Senate and the House of ...
Read moreAn independent review board has given Neuralink, billionaire entrepreneur Elon Musk's brain implant startup, approval to recruit paralysis patients for ...
Read moreThe Alzheimer's drug Leqembi recently received full approval from the Food and Drug Administration (FDA), marking the first drug to ...
Read moreNeuralink, the brain-chip company founded by Elon Musk, has announced that it has received approval from the US Food and ...
Read moreOn July 28, 2017, the world said goodbye to a little boy whose story touched many. After months of legal ...
Read moreBioterrorist? Bane of “Big Pharma”? Angel of equity? Industry gadfly? Unrealistic idealist? I have no doubt that some pharmaceutical industry ...
Read moreHow has the International community responded, what are possible solutions, and how does this affect reproductive and women's rights in Brazil? In ...
Read moreIt was tantamount to a Friday afternoon “news dump.” On Monday, December 21, 2015—amidst the final build-up to Christmas and ...
Read moreImpakter informs you through the ESG news site and empowers your business CSRD compliance and ESG compliance with its Klimado SaaS ESG assessment tool marketplace that can be found on: www.klimado.com
Registered Office Address
Klimado GmbH
Niddastrasse 63,
60329, Frankfurt am Main, Germany
IMPAKTER is a Klimado GmbH website
Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).
Office Hours - Monday to Friday
9.30am - 5.00pm CEST
stories [at] impakter.com
© 2025 IMPAKTER. All rights reserved.